Anzeige
❌
Mehr »
Sonntag, 25.10.2026 - Börsentäglich über 12.000 News
8 Millionen CAD eingesammelt, 21,45% Antimon entdeckt: Kanadas Bald-Hill-Projekt startet in die nächste Phase
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
NB

WKN: A3DNSU | ISIN: CA67059R1091 | Ticker-Symbol: J90
Tradegate
23.10.26 | 15:59
0,322 Euro
-4,73 % -0,016
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NUREXONE BIOLOGIC INC Chart 1 Jahr
5-Tage-Chart
NUREXONE BIOLOGIC INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,3240,35819:04
0,3160,36823.10.

Aktuelle News zur NUREXONE BIOLOGIC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08:30Nurexone Biologic mit EILMELDUNG: Könnte die Aktie jetzt komplett einbrechen? - Jetzt lesen, noch vor Börsenstart am Montag!
FrNurexone Biologic Inc: Nurexone doubles exosome production24
DoNurExone Biologic reports parallel bioreactors doubled exosome yield8
DoNurExone Biologic Inc: NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth11
09.10.Nurexone Biologic Inc: Nurexone touts rat data in optic nerve injury21
09.10.NurExone Biologic Inc: NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results20
18.09.Nurexone Biologic Inc: Nurexone hires RedChip for investor awareness78
18.09.NurExone Biologic Inc: NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update557TORONTO and HAIFA, Israel, Sept. 18, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biotechnology company developing exosome-based...
► Artikel lesen
NUREXONE BIOLOGIC Aktie jetzt für 0€ handeln
17.09.Nurexone Biologic Inc: Nurexone shareholders approve rollback at AGM51
16.09.NurExone Biologic Inc: NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update300TORONTO and HAIFA, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biotechnology company developing exosome-based...
► Artikel lesen
15.09.Nurexone Biologic Inc: Nurexone Biologic signs MOU with NanoPass Technologies34
14.09.NurExone Biologic Inc: NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications330TORONTO and HAIFA, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based...
► Artikel lesen
02.09.NurExone Biologic progresses towards a new regenerative therapy and sets sights on a potential NASDAQ listing48
31.08.NurExone Biologic reports Q2 results31
31.08.NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results732TORONTO and HAIFA, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biotechnology company developing exosome-based...
► Artikel lesen
21.08.Nurexone Biologic Inc: Nurexone Biologic schedules AGSM for Sept. 1545
21.08.NurExone Biologic Inc: NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy662Proposed share consolidation of up to 30:1 intended to support potential U.S. exchange listing and broaden investor appeal TORONTO and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic...
► Artikel lesen
20.08.NurExone Biologic Inc: NurExone Announces Closing of C$1,066,078 Private Placement493TORONTO, and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based...
► Artikel lesen
14.08.Nurexone Biologic Inc: Nurexone releases preclinical data supporting ExoPTEN54
14.08.NurExone Biologic Inc: NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model1.088TORONTO and HAIFA, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based...
► Artikel lesen
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,5